The RECONNECT Phase 3 trials
Two identically designed Phase 3, randomised, double-blind, placebo-controlled, multicentre trials (RECONNECT-1 and RECONNECT-2), enrolling approximately 1,247 premenopausal women with hypoactive sexual desire disorder in total, found that self-administered subcutaneous bremelanotide produced statistically significant improvements in sexual desire and significant reductions in desire-related distress compared with placebo. The most common treatment-emergent adverse events were nausea, flushing and headache, mostly mild to moderate.
- Study type
- Human trial
- Population
- Human, premenopausal women with HSDD (DSM-IV-TR criteria), two trials, combined n approximately 1247, multicentre
- Source
- 1 Kingsberg et al., 2019
Limitation: Both trials were funded and sponsored by the drug's developer, Palatin Technologies.
Limitations in full
Both trials were funded and sponsored by the drug's developer, Palatin Technologies. This is a conflict of interest readers should know about.